GlaxoSmithKline to buy Praecis for $54M

Showing no sign of buyer's fatigue, GlaxoSmithKline has agreed to pay $54.8 million for Waltham, MA-based Praecis Pharmaceuticals, which has been developing cancer therapies. The price values Praecis' stock at $5, double yesterday's closing price. GSK recently agreed to buy Domantis and forged a $2.1 billion licensing deal with Genmab, in addition to other deals that are designed to bulk up its pipeline.

"Praecis has created novel therapeutic programs and innovative chemical-synthesis and screening technology that will complement our own discovery capabilities," said Allen Oliff, senior vice president of molecular discovery research at Glaxo.

- check out the press release on the deal
- read the report on the buyout from

Suggested Articles

The FDA’s advisory committee chair has stepped down from reviewing the upcoming pandemic vaccines given her role in Moderna’s COVID-19 test.

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.